Chemo-Pharma [CPL] vs Ashok Leyland [ASHOKLEY] Detailed Stock Comparison
Chemo-Pharma
BSE
Loading...
Ashok Leyland
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Chemo-Pharma wins in 11 metrics, Ashok Leyland wins in 8 metrics, with 0 ties. Chemo-Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Chemo-Pharma | Ashok Leyland | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 11.95 | 25.16 | Chemo-Pharma |
| Price-to-Book Ratio | 2.52 | 6.49 | Chemo-Pharma |
| Debt-to-Equity Ratio | 44.70 | 315.50 | Chemo-Pharma |
| PEG Ratio | 0.61 | -0.36 | Ashok Leyland |
| EV/EBITDA | 13.68 | 11.93 | Ashok Leyland |
| Profit Margin (TTM) | 11.11% | 6.48% | Chemo-Pharma |
| Operating Margin (TTM) | 9.62% | 18.95% | Ashok Leyland |
| EBITDA Margin (TTM) | 9.62% | 18.95% | Ashok Leyland |
| Return on Equity | 20.97% | 19.61% | Chemo-Pharma |
| Return on Assets (TTM) | 11.26% | 3.80% | Chemo-Pharma |
| Free Cash Flow (TTM) | $41.66M | $-15.20B | Chemo-Pharma |
| Dividend Yield | N/A | 2.67% | N/A |
| 1-Year Return | -11.43% | 9.47% | Ashok Leyland |
| Price-to-Sales Ratio (TTM) | 1.39 | 1.60 | Chemo-Pharma |
| Enterprise Value | $4.59B | $1,223.74B | Ashok Leyland |
| EV/Revenue Ratio | 1.57 | 2.47 | Chemo-Pharma |
| Gross Profit Margin (TTM) | 29.30% | 41.70% | Ashok Leyland |
| Revenue per Share (TTM) | $51 | $84 | Ashok Leyland |
| Earnings per Share (Diluted) | $5.66 | $5.37 | Chemo-Pharma |
| Beta (Stock Volatility) | 0.23 | 0.30 | Chemo-Pharma |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Chemo-Pharma vs Ashok Leyland Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Chemo-Pharma | 0.43% | -0.38% | -7.64% | -11.83% | -19.75% | -42.01% |
| Ashok Leyland | -0.78% | 3.58% | 12.53% | 11.08% | 30.63% | 21.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Chemo-Pharma | -11.43% | 282.10% | 118.96% | 724.45% | 1,217.19% | 1,217.19% |
| Ashok Leyland | 9.47% | 67.60% | 237.39% | 205.78% | 607.26% | 1,699.87% |
News Based Sentiment: Chemo-Pharma vs Ashok Leyland
Chemo-Pharma
News based Sentiment: NEGATIVE
The significant financial losses reported in Q1 FY26, coupled with underperformance relative to the Sensex, create a concerning picture for investors. While the diversification strategy is a positive development, it doesn't immediately offset the current challenges. The volatile stock price and fluctuating investor participation add to the uncertainty.
Ashok Leyland
News based Sentiment: POSITIVE
Ashok Leyland demonstrated strong financial performance in Q2, secured a major order, and continued its strategic investment in battery technology. Positive analyst ratings and a rising stock price further reinforce a positive outlook for the company, indicating a significant and favorable month for investors.
Performance & Financial Health Analysis: Chemo-Pharma vs Ashok Leyland
| Metric | CPL | ASHOKLEY |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.05B | ₹788.13B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 32,878 | 14,522,610 |
| 90 Day Avg. Volume | 33,955 | 15,104,750 |
| Last Close | ₹67.73 | ₹134.01 |
| 52 Week Range | ₹66.00 - ₹128.00 | ₹95.93 - ₹138.20 |
| % from 52W High | -47.09% | -3.03% |
| All-Time High | ₹128.00 (Jan 06, 2025) | ₹264.65 (Aug 26, 2024) |
| % from All-Time High | -47.09% | -49.36% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.09% |
| Quarterly Earnings Growth | 0.34% | 0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.06% |
| Operating Margin (TTM) | 0.10% | 0.19% |
| Return on Equity (TTM) | 0.21% | 0.20% |
| Debt to Equity (MRQ) | 44.70 | 315.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹26.86 | ₹20.83 |
| Cash per Share (MRQ) | ₹1.01 | ₹20.20 |
| Operating Cash Flow (TTM) | ₹277.99M | ₹-26,049,600,000 |
| Levered Free Cash Flow (TTM) | ₹313.23M | ₹31.07B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.67% |
| Last 12-Month Dividend | ₹0.00 | ₹6.25 |
Valuation & Enterprise Metrics Analysis: Chemo-Pharma vs Ashok Leyland
| Metric | CPL | ASHOKLEY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 11.95 | 25.16 |
| Forward P/E | N/A | 17.43 |
| PEG Ratio | 0.61 | -0.36 |
| Price to Sales (TTM) | 1.39 | 1.60 |
| Price to Book (MRQ) | 2.52 | 6.49 |
| Market Capitalization | ||
| Market Capitalization | ₹4.05B | ₹788.13B |
| Enterprise Value | ₹4.59B | ₹1.22T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.57 | 2.47 |
| Enterprise to EBITDA | 13.68 | 11.93 |
| Risk & Other Metrics | ||
| Beta | 0.23 | 0.30 |
| Book Value per Share (MRQ) | ₹26.86 | ₹20.83 |
Financial Statements Comparison: Chemo-Pharma vs Ashok Leyland
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CPL | ASHOKLEY |
|---|---|---|
| Revenue/Sales | ₹697.42M | ₹116.57B |
| Cost of Goods Sold | ₹493.08M | ₹67.96B |
| Gross Profit | ₹204.34M | ₹48.61B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹67.12M | ₹22.19B |
| EBITDA | ₹79.31M | ₹25.96B |
| Pre-Tax Income | ₹55.13M | ₹8.91B |
| Income Tax | ₹12.13M | ₹2.34B |
| Net Income (Profit) | ₹42.99M | ₹6.58B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CPL | ASHOKLEY |
|---|---|---|
| Cash & Equivalents | ₹12.05M | ₹65.45B |
| Total Current Assets | ₹2.51B | ₹342.40B |
| Total Current Liabilities | ₹1.17B | ₹265.51B |
| Long-Term Debt | ₹109.50M | ₹365.68B |
| Total Shareholders Equity | ₹1.49B | ₹158.45B |
| Retained Earnings | N/A | ₹63.58B |
| Property, Plant & Equipment | ₹144.04M | ₹319.40M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CPL | ASHOKLEY |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CPL | ASHOKLEY |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 32,878 | 14,522,610 |
| Average Daily Volume (90 Day) | 33,955 | 15,104,750 |
| Shares Outstanding | 57.55M | 5.87B |
| Float Shares | 17.06M | 3.35B |
| % Held by Insiders | 0.70% | 0.40% |
| % Held by Institutions | 0.00% | 0.27% |
Dividend Analysis & Yield Comparison: Chemo-Pharma vs Ashok Leyland
| Metric | CPL | ASHOKLEY |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹6.25 |
| Last 12-Month Dividend Yield | N/A | 2.67% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹5.80 |
| 3-Year Avg Dividend Yield | N/A | 1.54% |
| 3-Year Total Dividends | ₹0.00 | ₹17.40 |
| Ex-Dividend Date | N/A | May 22, 2025 |